GENE ONLINE|News &
Opinion
Blog

2023-05-01| Trials & Approvals

Pfizer Racks Up Infant Indication for Pneumococcal Vaccine

by Reed Slater
Share To

After traversing through clinical trials, Pfizer announced that the FDA approved its pneumococcal vaccine, Prevnar 20, for infants and children. The 20-valent vaccine is now in direct competition with Merck’s 15-valent pneumococcal vaccine approved last year, indicated for the same infant population. 

A New and Improved Pneumococcal Vaccine

Prior to Prevnar 20, Pfizer developed Prevnar 13, which is approved for infants and children. Now, the new and improved 20-valent vaccine adds some additional protection, with seven extra serotypes found in pneumococcal cases. 

Pneumococcal disease encompasses a broad range of infections caused by the bacteria, Streptococcus pneumoniae. Infections under the pneumococcal umbrella can range from ear infections to pneumonia to bloodstream infections. Children with certain conditions like sickle cell disease, HIV infection, and diabetes are at a higher risk of developing pneumococcal-related infections. 

Pfizer is touting Prevnar 20 as offering the broadest serotype protection of any pneumococcal vaccine for infants after its most recent approval. The company said the seven added serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) account for approximately 37% of pneumococcal disease cases in children under five years old in the U.S. each year.

Annaliesa Anderson, Ph.D., Senior Vice President and Chief Scientific Officer of Vaccine Research and Development of Pfizer, said, “Today’s FDA approval of our vaccine, PREVNAR 20, now offers parents the ability to help protect their children against 20 pneumococcal serotypes in circulation, which represent the majority of pneumococcal disease in U.S. infants and children.”

Related Article: Pfizer and GSK Neck and Neck for First FDA-Approved RSV Vaccine 

Clinical Data Supporting the Approval

The Phase 3 clinical trial used to support the FDA’s decision consisted of nearly 2,000 healthy infant participants. The trial compared Prevnar 20’s safety and efficacy to Prevnar 13’s over the course of several months. 

In August last year, Pfizer announced results from the trial before submitting a Biologics License Application to the FDA. The study met its two co-primary objectives of non-inferiority of the percentage of participants with predefined serotype-specific immunoglobulin G concentrations after Dose 3 and NI of IgG geometric mean concentrations after Dose 4.

The data convinced the FDA and led to Prevnar 20’s most recent approval for infants and children. Pfizer can now set Prevnar 20 up against Merck’s 15-valent vaccine, VAXNEUVANCE, which gained approval last June for the same infant indication that Prevnar 20 just received.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
GeneOnline’s Pick – Top 10 Global Industry News Stories in 2023 (Part 2)
2024-01-15
JPM 2024: Pfizer’s Strategic Moves in the Obesity Drug Market and BioNTech’s Oncology Pipeline Expansion
2024-01-10
GeneOnline’s Pick: Top 10 Global Industry News Stories in 2023 (Part 1)
2024-01-08
LATEST
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
EVENT
Scroll to Top